Division of Pharmacy, Chiba University Hospital, Chiba, Japan.
J Clin Pharm Ther. 2019 Jun;44(3):479-481. doi: 10.1111/jcpt.12815. Epub 2019 Feb 15.
Determination of phenobarbital (PB) dosing during continuous haemodiafiltration (CHDF) requires evaluation of both the patient's own clearance and CHDF clearance.
Systemic clearance of PB in a 9-year-old female patient with Dravet syndrome, who was undergoing CHDF, was calculated by the Sawchuk-Zaske method, and clearance by CHDF was calculated as the difference between PB levels in influx and efflux, adjusted for the blood purification conditions. Dosage adjustment produced seizure control.
Adjusting PB dose by evaluating the patient's own PB clearance as well as that by CHDF resulted in accurate control of PB level and a reduction in the occurrence of seizures.
在连续血液透析滤过（CHDF）期间确定苯巴比妥（PB）的剂量需要评估患者自身清除率和 CHDF 清除率。
通过 Sawchuk-Zaske 方法计算患有 Dravet 综合征的 9 岁女性患者在接受 CHDF 期间的 PB 全身清除率，并通过 CHDF 清除率计算 PB 水平在流入和流出之间的差异，调整血液净化条件。剂量调整产生了癫痫控制。
通过评估患者自身 PB 清除率以及 CHDF 的清除率来调整 PB 剂量，可准确控制 PB 水平并减少癫痫发作的发生。
